Some patients may discuss switching from semaglutide to tirzepatide if progress has slowed, side effects are difficult to manage, appetite control is not adequate or the provider believes another option may better fit the patients metabolic needs
Technical details are summarized in the FDA prescribing information and independent overviews such as StatPearls (both describe the ~1-week half-life and slow elimination)
The cloudy liquid should not be used as it may indicate incorrect storage conditions or expired products
We utilize laboratory testing when appropriate to assess: Metabolic health Nutrient status Hormonal influences Other underlying factors that may impact weight This allows us to make informed, individualized decisions, rather than relying on assumptions
When semaglutide does not work Not everyone responds the same way
[79] Trials for cardiovascular health [edit] In March 2024, the US Food and Drug Administration expanded the indication for semaglutide (brand name Wegovy) to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and who are either obese or overweight